Description: Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Home Page: www.lexariabioscience.com
LEXX Technical Analysis
#100 – 740 McCurdy Road
Kelowna,
BC
V1X 2P7
Canada
Phone:
250-765-6424
Officers
| Name | Title |
|---|---|
| Mr. Christopher A. Bunka | Chairman & CEO |
| Mr. John M. Docherty M.Sc. | Pres & Director |
| Mr. Gregory John Downey CMA, CPA | CFO & Treasurer |
| Vanessa Carle | Head of Legal |
| Dr. Philip N. Ainslie Ph.D. | Advisor & Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1936 |
| Price-to-Sales TTM: | 65.0074 |
| IPO Date: | 2006-10-10 |
| Fiscal Year End: | August |
| Full Time Employees: | 7 |